Anbio Biotechnology Class A Ordinary Shares (NNNN) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · United States · ISIN KYG0367B1059

Price
4.05 USD
Market cap
177.76 m USD
P/E (2025)
27.76
P/S (2025)
20.56
Dividend yield
0.00 %
Net margin
74.06 %
Return on equity (ROE)
21.24 %
Return on assets (ROA)
21.17 %

Anbio Biotechnology Class A Ordinary Shares financials

Fiscal year20242025
Revenue8.19 m USD8.65 m USD
Gross profit5.89 m USD7.54 m USD
Operating income2.00 m USD5.77 m USD
EBIT2.00 m USD5.77 m USD
Net income2.37 m USD6.40 m USD
Diluted EPS – continuing operations0.06 USD0.15 USD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.